Drug Type Small molecule drug |
Synonyms Malol, Prunol, Urson + [2] |
Action inhibitors |
Mechanism Akt inhibitors(Proto-oncogene proteins c-akt inhibitors), Enzymes inhibitors, FADS2 inhibitors(fatty acid desaturase 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC30H48O3 |
InChIKeyWCGUUGGRBIKTOS-GPOJBZKASA-N |
CAS Registry77-52-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Ursolic Acid | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metabolic Syndrome | Phase 2 | Mexico | 01 Sep 2014 | |
Stomach Cancer | Preclinical | China | 01 Jul 2025 | |
Parkinson Disease | Preclinical | India | 24 Jun 2025 | |
Parkinson Disease | Preclinical | India | 24 Jun 2025 | |
Non-Small Cell Lung Cancer | Preclinical | China | 27 May 2025 | |
Castration-Resistant Prostatic Cancer | Preclinical | United States | 28 Apr 2025 |
Phase 2 | 10 | Strength Training+Ursolic Acid (UA and Exercise in Paraplegia Group) | ryrzcttciy(jjabdsgkvc) = suvrdfrnbs kjwxmidgdd (ytweuckzog, 2642.65) View more | - | 21 May 2025 | ||
(UA in Tetraplegia Group) | ryrzcttciy(jjabdsgkvc) = hujeefosuv kjwxmidgdd (ytweuckzog, 1885.21) View more | ||||||
Phase 2/3 | - | (UA supplementation) | disjmnphmr(hbzggbhrcp) = fhvmkyqlmo aygyqfuhsi (xakxibbvjy ) | Negative | 01 Aug 2021 | ||
(Placebo supplementation) | - | ||||||
Phase 2 | 24 | (Ursolic Acid) | axthwzexos(llejlbdojh) = orvvtgboub etrxtourzj (vasptedflm, 1.2) View more | - | 08 Oct 2020 | ||
Placebo (Placebo) | axthwzexos(llejlbdojh) = zahzfakwaj etrxtourzj (vasptedflm, 1.4) View more |